

comprising administering to the subject an effective amount of an HICP protein or biologically active portion thereof, to thereby treat or prevent the disease or disorder.

Support for amended Claim 53 and new Claims 62 and 63 is found throughout the specification. For example, support for amended Claim 53 is found at least on page 5, line 25-27. Support for Claim 62 is found at least in page 7, line 21 to page 8, line 2. Support for Claim 63 is found at least in Example 5, in which an extract containing HICP is contacted to a heparin-responsive cell to thereby increase cellular proliferation, thus exemplifying the claimed embodiment.


Applicant submits that the pending claims are in condition for allowance.

SUMMARY

In view of the foregoing remarks, consideration and allowance of the present application is respectfully requested. If a telephone conversation with Applicant's Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicant's Attorney at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Amy E. Mandragouras, Esq.
Registration No. 36,307
Attorney for Applicant

28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Dated: May 6, 2002

Appendix A

Version with Markings to Show Changes Made to Amended Claims

53. (Amended) A method for treating a disorder characterized by aberrant [aberrant] cell proliferation in a subject, comprising [by] administering to the [a] subject [having the disorder] a HICP agent [which alters cell proliferation relative to cell proliferation in the absence of the agent].